Important Safety Information
Indications for Use (IFU): The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.
Important Safety Information (ISI): Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
Disclaimer: The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in the videos and information on this webpage are not indicative of typical or future results.
Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.
Only On MRIdian
James Good, MD, Clinical Director of SBRT, GenesisCare Oxford
Patient: 54-yo female; ER(+) HER2(-) primary breast tumor, previously Tx w/ lumpectomy and post-op RT; presented with 3 liver mets on FDG PET and MRI
Treatment Options: Surgery too risky, not able to get complete disease; standard radiation not an option
Challenge: Lesion location: Very susceptible to motion; requires complex setup w/ abdominal compression and fiducials; movement up to 2 cm would lead to large ITV and irradiating healthy tissue; conventional Linac would compromise PTV dose to meet OAR constraints; likely reduce overall dose to avoid exceeding mean liver tolerance
MRIdian: 35 Gy in 5 Fx, keeping OARs in tolerance; daily adaptation for ablative dose to tumor while keeping critical structures within tolerance; real-time automated beam gating with patient directed breath-hold allowed accurate dose delivery
Outcome: Able to deliver 50 Gy to three lesions. Three-month follow-up shows clear ablation zone and elimination of tumor
Case courtesy of Dr. Good – GenesisCare Oxford. Results of this case study are not predictive of future results.
Only On MRIdian
“MRIdian may radically change pediatric radiotherapy indications.”
Enis Özyar, MD, Professor of Radiation Oncology, Acibadem Maslak Hospital
Patient: 15-mo with very rare pediatric metastatic liver tumor and huge celiac lymph node compressing biliary system
Treatment Options: RT not typically offered due to risk to anatomy—small structure size and motion; patient not a candidate for chemo
Challenge: Understanding efficacy and safety of shorter hypofractionation schemes is critical to improving pediatric palliative care. In this pediatric case, we aimed to deliver treatment within a short period of time with minimal toxicity. Technically, it was not possible to ideally treat this mass with other radiotherapy systems as we needed fiducial markers and adaptive approach
MRIdian: 25 Gy in 5 Fx, every other day
Outcome: ~40% reduction in size over course of Tx making on-table adaptive re-planning essential; would have never known tumor was shrinking if treated with x-ray-guided system
Case courtesy of Prof. Ozyar – Acibadem Hospital Maslak. Results of this case study are not predictive of future results.
Key Study Summary
MRIdian In The News Related To Liver Cancer
Carbone Cancer Center, University of Wisconsin - Madison, WI - 2:27 minutes
MDs: Paul Harari, MD; Michael Bassetti, MD, PhD
Producer: UW Health
Liver cancer
- MRI and radiation therapy are delivered at the same time
- Gate the radiation to move with the tumor
- Minimizes radiation risk to organs; diminishing the amount of normal tissue that gets exposed to radiation
February 13, 2015
Sorry, no News Articles found.
Scientific Presentations Related To Liver Cancer
MRI-Guided Liver Radiation: Seeing What You are Missing
Michael Bassetti, MD, PhD
Carbone Cancer Center, University of Wisconsin – Madison
ASTRO 2019
Dr. Bassetti has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Liver MRI-Guided Stereotactic Body Radiation Therapy (SBRT)
Lorraine Portelance, MD
Sylvester Comprehensive Cancer Center, University of Miami Health System
ASTRO 2019
Dr. Portelance has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.
ViewRay MRIdian Linac: The Miami Cancer Institute Clinical Experience
Michael Chuong, MD
Miami Cancer Institute, Baptist Health South Florida
ASTRO 2018
Dr. Chuong has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Prospective Experience with Real-Time Online Adaptive Radiotherapy for Abdominal and Pelvic Malignancies
Lauren Henke, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
ASTRO 2018
Dr. Henke has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.
Quantitative Radiomics of Daily 0.35T MR Images for Prediction of Tumor Response in Pancreas and Liver
John Chetley Ford, PhD
Sylvester Comprehensive Cancer Center, University of Miami Health System
ASTRO 2018
Dr. Ford has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Plan QA for Adaptive RT – UCLA Approach
Youming Yang, Ph.D.
UCLA Health, Jonsson Comprehensive Cancer Center – Los Angeles, CA
AAPM 2017
Dr. Yang has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Sorry, no videos found.
